NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Royalty Pharma plc (RPRX) Stock Analysis

Royalty Pharma plc (RPRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

RPRX

$62.15

−$0.10 (−0.16%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RPRX with… →

RPRX Key Statistics

As of Oct 21, 2026
Trading
Open
$62.10
Previous Close
$62.25
Day's Range
62.00–62.90
52-Week Range
35.92–64.38
Volume
2.74M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.41
Valuation
Market Cap
$35.91B
P/E Ratio
33.06
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
10.72
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.45
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
14.16
EPS (ttm)Profit attributable to each share over the last twelve months.
1.88
Financials (FY)
Revenue (FY)
$2.38B+5.06%
Net Income (FY)
$770.95M−10.25%
Profit marginThe share of revenue left as profit after all costs and taxes.
32.02%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
445.28M
1-Year Return
+68.36%
Dividend and dates
Dividend
$0.94+1.51%
Ex-Dividend Date
November 13, 2026
Earnings Date
November 4, 2026
Avg Volume
2.97M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, RPRX closed at $62.15, +68.36% over 1 year.

Royalty Pharma plc (RPRX) has a market capitalization of $35.91B.

In fiscal 2025, RPRX reported revenue of $2.38B.

RPRX Stock Return by Calendar Year

Royalty Pharma plc (RPRX) return since Jun 2020: what $10,000 became

1 year
$10,000 $16,836
+68.36%
5 years
$10,000 $18,553
+85.53%
Since Jun 2020
$10,000 $15,945
+59.45%

If you had invested $10,000 in Royalty Pharma plc (RPRX) at the close on June 16, 2020, the earliest close on record here, it would have been worth $15,945 at the close on October 21, 2026: +59.45% in total, +7.63% a year, with dividends reinvested, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+62.40%
2025+55.29%
2024−6.36%
2023−27.08%
2022+0.99%
2021−19.09%
2020 (partial year)+13.33%

As of October 21, 2026.

RPRX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.38B$770.95M32.4%
2024$2.26B$858.98M37.9%
2023$2.35B$1.13B48.2%
2022$2.24B$42.83M1.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.38B—$1.56B$770.95M32.4%
2024$2.26B—$1.29B$858.98M37.9%
2023$2.35B—$1.49B$1.13B48.2%
2022$2.24B—$922.89M$42.83M1.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RPRX Dividend History

$0.88+4.8% vs 2024

Dividends per share, 2025 · 4 payments

YearDividends per sharePaymentsChange
2026*$0.713—
2025$0.884+4.8%
2024$0.844+5.0%
2023$0.804+5.3%
YearDividends per sharePaymentsChange
2026 (partial year)$0.713—
2025$0.884+4.8%
2024$0.844+5.0%
2023$0.804+5.3%
2022$0.764+11.8%
2021$0.684+126.7%
2020$0.302—

Most recent payment: $0.24 per share, ex-dividend August 14, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

RPRX Valuation vs Biotechnology Median

Median of 608 stocks
MetricRPRXBiotechnology medianvs median
P/E33.0616.6099% above
P/S ratio14.1613.306% above
Profit margin32.02%−38.31%70.3 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Royalty Pharma plc (RPRX) at $35.91B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 100.

The most recent close on file for RPRX is $62.15, dated October 21, 2026. That is −$0.10 (−0.16%) against the previous close. The 52-week range on file runs from $35.92 to $64.38. The latest close sits 73.05% above that 52-week low.

Financial Health

In fiscal 2025, Royalty Pharma plc reported revenue of $2.38B. That is +5.06% against the prior fiscal year, when revenue was $2.26B. The same year closed with net income of $770.95M. That is −10.25% against the prior fiscal year. The reported profit margin is 32.02%. That is 70.3 percentage points above the Biotechnology median of −38.31%. Trailing earnings per share are 1.88.

Across the 4 fiscal years on file, revenue moves from $2.24B in 2022 to $2.38B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

RPRX trades at a trailing price-to-earnings ratio of 33.06. That is 99.16% above the Biotechnology median of 16.6. On forward earnings the ratio is 10.72. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.45. The price-to-sales ratio is 14.16. On price-to-sales that is 6.49% above the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Beta against the wider market is reported at 0.41. Annualized volatility over the trailing 6 years is 25.51%. Over the trailing twelve months the total return is +68.36%. Measured over 5 years, that is +13.16% a year compounded.

Growth & Income

Shareholders receive a dividend, yielding 1.51% on the latest price. That is 0.8 percentage points above the Biotechnology median yield of 0.69%. The indicated annual rate is $0.94 a share. The ex-dividend date on file is November 13, 2026. Dividends are recorded for 7 calendar years; 2026 shows 3 payments totalling $0.71 a share. The year before, 2025, totalled $0.88 a share.

The strongest complete calendar year on file is 2025 at +55.29%; the weakest is 2023 at −27.08%. Of the 5 complete calendar years on file, 2 finished higher. 2026 is still running; the total return is +62.40% year to date.

Peer Comparison

Royalty Pharma plc (RPRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Royalty Pharma plc RPRX $35.91B 33.1
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Royalty Pharma plc trades at a P/E of 33.1.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Royalty Pharma plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Visit website →